EGFR-tirozinkináz-inhibitorok alkalmazása tüdõrákban

szenzitivitás és rezisztencia

Translated title of the contribution: EGFR tyrosine kinase inhibitors in lung cancer management: Sensitivity and resistance

Moldvay Judit, I. Peták

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.

Original languageHungarian
Pages (from-to)38-49
Number of pages12
JournalMagyar Onkologia
Volume56
Issue number1
Publication statusPublished - 2012

Fingerprint

Protein-Tyrosine Kinases
Lung Neoplasms
Molecular Targeted Therapy
Translational Medical Research
Mutation
Therapeutics
Pathologists
Oncologists
Pulmonologists

ASJC Scopus subject areas

  • Oncology

Cite this

EGFR-tirozinkináz-inhibitorok alkalmazása tüdõrákban : szenzitivitás és rezisztencia. / Judit, Moldvay; Peták, I.

In: Magyar Onkologia, Vol. 56, No. 1, 2012, p. 38-49.

Research output: Contribution to journalArticle

@article{57f7a2711c57464f9a47e2ae105d34f2,
title = "EGFR-tirozinkin{\'a}z-inhibitorok alkalmaz{\'a}sa t{\"u}d{\~o}r{\'a}kban: szenzitivit{\'a}s {\'e}s rezisztencia",
abstract = "Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.",
keywords = "EGFR activating mutation, EGFR resistance mutation, EGFR-TKI, Lung cancer, Molecular targeted therapy",
author = "Moldvay Judit and I. Pet{\'a}k",
year = "2012",
language = "Hungarian",
volume = "56",
pages = "38--49",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - EGFR-tirozinkináz-inhibitorok alkalmazása tüdõrákban

T2 - szenzitivitás és rezisztencia

AU - Judit, Moldvay

AU - Peták, I.

PY - 2012

Y1 - 2012

N2 - Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.

AB - Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.

KW - EGFR activating mutation

KW - EGFR resistance mutation

KW - EGFR-TKI

KW - Lung cancer

KW - Molecular targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84860603283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860603283&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 38

EP - 49

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -